GLUE vs NVS: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

NVS is the larger of the two ($286.41B market cap): the incumbent the market prices for continued execution (15.27x forward earnings, beta 0.45). GLUE is the smaller challenger ($745.13M), still expected to post a loss next year: more room to run, but more to prove. On the numbers, NVS leads on both counts: faster expected revenue growth (7% vs -40%) and expected profits next year, which GLUE does not have. The case for GLUE rests on its own driver (Novartis partnerships): if you believe in that, GLUE fits; if you believe in what the numbers show today, NVS does.

GLUE vs NVS: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricGLUENVSWhat it tells you
Market cap$745.13M$286.41BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-5.0015.27Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.380.45Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range1% of range58% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.507.69How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how GLUE and NVS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GLUE and NVS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GLUE and NVS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Monte Rosa Therapeutics (GLUE) do?

Monte Rosa Therapeutics develops molecular glue degraders (MGDs), small molecules that recruit the cell's natural ubiquitin-proteasome system to selectively eliminate target proteins that are otherwise hard to drug. Its QuEEN discovery engine pairs AI-guided chemistry with structural biology and proteomics to design these degraders. The pipeline centers on three programs: MRT-6160 (a VAV1-directed degrader for immune-mediated diseases, licensed to Novartis), MRT-8102 (a NEK7/NLRP3-pathway degrader for inflammatory and cardiovascular disease that posted positive interim Phase 1 data in January 2026 and full GFORCE-1 Phase 1 results in October 2026), and MRT-2359 (a MYC-pathway degrader in oncology).

Full GLUE guide

What does Novartis AG (NVS) do?

Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025. Revenue was about $56.7 billion in 2025, roughly 10% above 2024, and trailing twelve-month revenue is about $57.4 billion with net income near $10.0 billion.

Full NVS guide

GLUE vs NVS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • GLUE drivers: Novartis partnerships; MRT-8102 in inflammation and cardiovascular disease.
  • NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Monte Rosa is pre-product and unprofitable, so it depends on clinical success and continued financing. For NVS, the dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed.

GLUE or NVS: which should you pick?

If the story you believe is GLUE's (Novartis partnerships), GLUE is the more direct way to own it; if it is NVS's (Priority growth brands offsetting the cliff), NVS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GLUE and NVS guides.

GLUE vs NVS: the full fundamentals

GLUE. Revenue is collaboration and license income (largely Novartis-related), not product sales, and it varies with deal timing; the October 2026 $37.5 million Novartis milestone falls after the September figures. Standard valuation multiples like P/E do not apply to a pre-profit biotech; with cash near $583 million against a market value around $744 million, the market is pricing relatively little platform value. The average target from eight analysts is about $25, roughly three times the November 20 close.

NVS. At about $152, NVS trades near 29 times trailing earnings but only about 15 times forward estimates, a gap that widened after a third quarter in which reported profit fell to about $1.2 billion while core EPS beat. Analysts expect EPS of about $9.07 in 2026 and $9.93 in 2027. The analyst mean target of roughly $157 sits close to the current price, so how fast the growth brands keep absorbing the generic erosion, and the run of pipeline readouts into 2027, matter more than any single trailing figure. Figures are approximate and tied to the asOf date; verify live numbers before acting.

Headline figures (approximate, November 2026): GLUE shows market cap ~$744M, share price ~$8.71 (down ~43% YTD), revenue (ttm) ~$70M (collaboration income), net loss (ttm) ~-$131M; NVS shows revenue (ttm) ~$57.4B; Q3 2026 revenue ~$15.03B, up ~5% year over year, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix offsetting Entresto's generic decline, margins (ttm) ~75% gross, ~34% operating, ~17.5% net, net income (ttm) ~$10.0B.

The bottom line: GLUE vs NVS

GLUE and NVS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined GLUE and NVS exposure against your real portfolio. It is not an investment adviser.

Wondering how GLUE or NVS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Monte Rosa Therapeutics

Ask Walnut's AI anything about GLUE and see how it fits what you own.

FAQ

What is the difference between GLUE and NVS?

+

Monte Rosa Therapeutics develops molecular glue degraders (MGDs), small molecules that recruit the cell's natural ubiquitin-proteasome system to selectively eliminate target proteins that are otherwise hard to drug. Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is GLUE or NVS the better stock?

+

Neither is universally better. NVS is the larger incumbent; GLUE is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, GLUE or NVS?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both GLUE and NVS?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of GLUE vs NVS?

+

GLUE: Monte Rosa is pre-product and unprofitable, so it depends on clinical success and continued financing. Molecular glue degraders remain a relatively young modality, and early positive biomarker data (such as CRP reductions) do not guarantee later-stage clinical or regulatory success. Much of the company's headline value comes from Novartis milestone potential that is contingent and may never be earned. The stock is volatile and can move sharply on single data points, and future capital raises could dilute shareholders. Competition in targeted protein degradation is intensifying across both large pharma and specialized biotechs. The shares fell about 40% over the three months to November 20, 2026 and about 20% in the past month, to near their 52-week low of about $8.63, even after the positive GFORCE-1 readout and two Novartis milestones, showing how sentiment can move independently of reported biomarker data. Partner income is lumpy: the third-quarter profit came almost entirely from a single $50 million milestone, and analysts expect revenue of under $4 million in the first quarter of 2027. NVS: The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. Analysts expect 2026 EPS to be about flat before rising about 10% in 2027, and reported earnings fell about 69% year over year in the latest quarter. Pipeline risk is structural because late-stage trials can fail and regulators can reject or delay approvals, turning expected future revenue into a write-off, as pelacarsen's failed HORIZON outcomes trial did in 2026. Large acquisitions such as Avidity add integration and financing risk and raised debt, which stood at about $48 billion against about $8.9 billion of cash at September 30, 2026. US drug-pricing policy, potential pharmaceutical tariffs, and pricing pressure are outside the company's control and could compress margins, and in November 2026 the CEO warned that US limits on investment in Chinese biotech could hurt drug development. Because NVS is a Swiss ADR, US investors also carry dollar-versus-Swiss-franc currency risk, and Swiss dividend withholding tax reduces net income for some holders. Concentration in a handful of growth drugs means a single clinical or commercial setback can move the stock.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell GLUE or NVS; figures are approximate and dated (as of November 2026). Verify current data before investing.